Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can effectively shrink or eliminate tumors in ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s immune system to target and eliminate cancer cells appeared to reduce the ...

Thousands of patients will be offered a new injectable form of an immunotherapy drug that takes minutes.

After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives.

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Will your melanoma be caught in time? A new campaign is calling on more doctors, particularly in states like Florida with ...